Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MNKD | PRESS-RELEASE | neutral | 5/10 | MannKind announced completion of patient randomization in the U.S. Phase 1b INFLO-1 trial and enrollment of the first pa | Jun 3, 2026 |
| MLYS | PRESS-RELEASE | bullish | 7/10 | Mineralys Therapeutics repurchased its royalty obligation to Tanabe for $200M upfront (up to $100M in milestones), secur | Jun 3, 2026 |
| PCVX | PRESS-RELEASE | neutral | 4/10 | Vaxcyte dosed the first participant in a Phase 1 first-in-human study of VAX-A1, a prophylactic vaccine candidate for Gr | Jun 2, 2026 |
| GLUE | PRESS-RELEASE | neutral | 2/10 | Monte Rosa Therapeutics granted inducement equity awards totaling 20,050 stock options and 4,400 RSUs to four new non-ex | Jun 2, 2026 |
| PRAX | PRESS-RELEASE | neutral | 1/10 | Praxis Precision Medicines granted 2,754 restricted stock units to 13 new non-executive employees under its 2024 Inducem | Jun 2, 2026 |
| NRXP | PRESS-RELEASE | bearish | 6/10 | NRx Pharmaceuticals announced an underwritten public offering of common stock, with an option for underwriters to purcha | Jun 2, 2026 |
| LEGN | PRESS-RELEASE | bullish | 7/10 | Legend Biotech announced promising Phase 1 data for LB2501, an in vivo CD19/CD20 dual-targeting CAR-T therapy, showing 1 | Jun 2, 2026 |
| CRDF | PRESS-RELEASE | bullish | 8/10 | Cardiff Oncology announced positive Phase 2 data for onvansertib in first-line RAS-mutated mCRC at ASCO 2026, showing a | Jun 2, 2026 |
| KURA | PRESS-RELEASE | bullish | 6/10 | Kura Oncology announced publication in Blood of updated Phase 1a/b KOMET-007 data for ziftomenib + venetoclax + azacitid | Jun 2, 2026 |
| CADL | PRESS-RELEASE | bullish | 8/10 | Candel Therapeutics announced publication of its pivotal Phase 3 trial results for aglatimagene (CAN-2409) in localized | Jun 2, 2026 |
| LNTH | PRESS-RELEASE | neutral | 4/10 | Lantheus announced that an image from its LNTH-2513 (18F-GP1) PET/CT trial for deep vein thrombosis (DVT) was awarded SN | Jun 2, 2026 |
| QUCY | PRESS-RELEASE | neutral | 4/10 | Quantum Cyber (QUCY) announced an amendment to its BP United license agreement, taking direct control of drone manufactu | Jun 2, 2026 |
| LFCR | PRESS-RELEASE | neutral | 4/10 | Lifecore Biomedical announced a manufacturing services agreement with a leading ophthalmic disease management provider f | Jun 2, 2026 |
| TLX | PRESS-RELEASE | neutral | 4/10 | Telix Pharmaceuticals and United Imaging signed an MOU to evaluate a strategic research collaboration integrating Telix' | Jun 2, 2026 |
| VERA | PRESS-RELEASE | bullish | 7/10 | Vera Therapeutics announced FDA alignment on a revised, earlier eGFR analysis plan for atacicept in IgA Nephropathy, pul | Jun 2, 2026 |
| BYSI | PRESS-RELEASE | bullish | 7/10 | BeyondSpring presented updated Phase 2 data at ASCO 2026 for its triple combination (pembrolizumab + Plinabulin + doceta | Jun 2, 2026 |
| TRDA | PRESS-RELEASE | neutral | 4/10 | Entrada Therapeutics announced that an independent DMC recommended dose escalation to 10 mg/kg in Cohort 2 of the ELEVAT | Jun 2, 2026 |
| ZNTL | PRESS-RELEASE | neutral | 2/10 | Zentalis granted 191,000 non-qualified stock options to two newly hired employees as an inducement for employment, with | Jun 1, 2026 |
| TLX | PRESS-RELEASE | bullish | 6/10 | Telix presented Phase 3 ProstACT Global Part 1 safety data at ASCO 2026 for TLX591-Tx in mCRPC, showing acceptable toler | Jun 1, 2026 |
| XCUR | PRESS-RELEASE | neutral | 4/10 | Exicure received a Nasdaq non-compliance notice for late filing of its Q1 2026 10-Q, but filed the report on May 29, 202 | Jun 1, 2026 |
| LEGN | PRESS-RELEASE | bullish | 6/10 | Legend Biotech presented early clinical data for LB2102 (DLL3 CAR-T) in SCLC/LCNEC at ASCO, showing manageable safety an | Jun 1, 2026 |
| AIM | PRESS-RELEASE | neutral | 4/10 | AIM ImmunoTech announced ahead-of-schedule enrollment completion for its Phase 2 DURIPANC trial (Ampligen + Imfinzi in m | Jun 1, 2026 |
| FATE | PRESS-RELEASE | bullish | 6/10 | Fate Therapeutics presented early Phase 1 data for FT836, an off-the-shelf CAR T-cell therapy targeting MICA/B in solid | Jun 1, 2026 |
| IRON | PRESS-RELEASE | neutral | 4/10 | Disc Medicine launched an expanded access program (EAP) for bitopertin in erythropoietic protoporphyria (EPP)/X-linked p | Jun 1, 2026 |
| CLRB | PRESS-RELEASE | bullish | 7/10 | Cellectar Biosciences announced positive Phase 2 CLOVER WaM data at ASCO for iopofosine I 131 in post-BTKi Waldenström m | Jun 1, 2026 |
| JSPR | PRESS-RELEASE | bearish | 8/10 | Jasper Therapeutics announced a comprehensive review of strategic alternatives, including a potential sale, licensing, m | Jun 1, 2026 |
| IMTX | PRESS-RELEASE | bullish | 6/10 | Immatics reports extended Phase 1b data for anzu-cel (PRAME TCR T-cell therapy) in metastatic melanoma at ASCO 2026, sho | Jun 1, 2026 |
| NXTC | PRESS-RELEASE | bullish | 7/10 | NextCure announced positive Phase 1 dose escalation data for SIM0505, a CDH6-targeting ADC, at ASCO 2026, showing a 55% | Jun 1, 2026 |
| ELAB | PRESS-RELEASE | neutral | 4/10 | PMGC Holdings (ELAB) announced a non-binding LOI to acquire a 76% controlling interest in a privately held precision mac | Jun 1, 2026 |
| CGTX | PRESS-RELEASE | neutral | 2/10 | Cognition Therapeutics announced its CEO will present at the Jefferies Global Healthcare Conference (June 4) and H.C. Wa | Jun 1, 2026 |